Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination with Chemotherapy in Frontline Ovarian Cancer
The goal of this clinical research study is to learn about the safety of giving the combination of pembrolizumab, carboplatin, and paclitaxel to patients with high-grade epithelial non-mucinous ovarian, primary peritoneal, or Fallopian tube cancer. Researchers want to find out how the disease responds to therapy with pembrolizumab.
Treatment Location: N/A
IRB Review and Approval Date: 07/05/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: